Lower incidence of chronic graft-versus-host disease after ruxolitinib plus extracorporeal photopheresis versus ruxolitinib alone in steroid-refractory acute graft-versus-host disease following allogeneic stem cell transplantation.
Iryna Lastovytska, Silke Heidenreich, Evgeny Klyuchnikov, Christian Niederwieser, Nico Gagelmann, Johanna Richter, Radwan Massoud, Kristin Rathje, Tetiana Perekhrestenko, Gaby Zeck, Catherina Lück, Dietlinde Janson, Christine Wolschke, Francis Ayuk, Nicolaus Kröger
{"title":"Lower incidence of chronic graft-versus-host disease after ruxolitinib plus extracorporeal photopheresis versus ruxolitinib alone in steroid-refractory acute graft-versus-host disease following allogeneic stem cell transplantation.","authors":"Iryna Lastovytska, Silke Heidenreich, Evgeny Klyuchnikov, Christian Niederwieser, Nico Gagelmann, Johanna Richter, Radwan Massoud, Kristin Rathje, Tetiana Perekhrestenko, Gaby Zeck, Catherina Lück, Dietlinde Janson, Christine Wolschke, Francis Ayuk, Nicolaus Kröger","doi":"10.3324/haematol.2024.286824","DOIUrl":null,"url":null,"abstract":"<p><p>We compared long-term outcomes in 78 patients with steroid-refractory acute graft-versushost disease (SR-aGVHD) treated at the University Medical Center Hamburg, Germany between December 2015 and August 2022 who received either ruxolitinib alone (Ruxo, n=29) or Ruxo plus extracorporeal photopheresis (Ruxo-ECP, n=49). Patients were well balanced between both arms except for SR-aGVHD grade IV which was higher in the Ruxo-ECP group (45% vs. 14%, p.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":8.2000,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Haematologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3324/haematol.2024.286824","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
We compared long-term outcomes in 78 patients with steroid-refractory acute graft-versushost disease (SR-aGVHD) treated at the University Medical Center Hamburg, Germany between December 2015 and August 2022 who received either ruxolitinib alone (Ruxo, n=29) or Ruxo plus extracorporeal photopheresis (Ruxo-ECP, n=49). Patients were well balanced between both arms except for SR-aGVHD grade IV which was higher in the Ruxo-ECP group (45% vs. 14%, p.
期刊介绍：
Haematologica is a journal that publishes articles within the broad field of hematology. It reports on novel findings in basic, clinical, and translational research.
Scope:
The scope of the journal includes reporting novel research results that:
Have a significant impact on understanding normal hematology or the development of hematological diseases.
Are likely to bring important changes to the diagnosis or treatment of hematological diseases.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
